Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romosozumab Phase 2 in Japanese Postmenopausal Osteoporosis
NCT01992159Phase 2Completed
- Sponsor
- Amgen
- Start
- Oct 2012
- Primary completion
- Oct 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of romosozumab in postmenopausal osteoporosis, sponsored by Amgen. Started Oct 2012; status: completed.
02
Drugs
romosozumab
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT01992159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01992159.